Key result
Anticoagulant reversal with idarucizumab and andexanet alfa faces ongoing dosing, monitoring, and thrombotic risk challenges.
Why the study?
The global rise in anticoagulant use has increased major bleeding events that warrant timely and effective pharmacologic reversal.
This review provides a comprehensive overview of current pharmacologic reversal strategies for anticoagulants, highlighting specific antidotes and ongoing clinical challenges such as dosing, monitoring, and thrombotic risk mitigation.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“There is no [single] optimal approach. The effective and safe approach to [managing] patients who bleed under DOACs always has to consider surgery- and patient-specific factors.”
“If specific reversal agents of DOACs are not available, the use of prothrombin complex concentrates is recommended, a practice supported by scientific evidence. However, in the context of trauma, many studies are observational in nature, which limits the ability to offer definitive therapeutic recommendations.”
Reversal requires individualized assessment of agent and patient factors; leaves open optimal strategies for LMWH-associated bleeding.
The global rise in anticoagulant use has increased the number of major bleeding events that warrant timely and effective pharmacologic reversal. Reversal strategies should be informed by the pharmacodynamic and pharmacokinetic features of the anticoagulant and antidote, regulatory indications, quality of evidence, patient-specific factors, and availability of treatment options. Protamine sulfate neutralizes unfractionated heparin, whereas no specific antidotes exist for low-molecular-weight heparins or fondaparinux. Four-factor prothrombin complex concentrates effectively reverse vitamin K antagonists. Idarucizumab specifically reverses dabigatran, although delayed dabigatran rebound can occur. Andexanet alfa targets direct oral factor Xa inhibitors, but uncertainties regarding the efficacy-safety balance, monitoring, rebound, perioperative use, and cost have prompted off-label use of four-factor prothrombin complex concentrates, for which stronger evidence is needed. Key challenges remain, including determination of appropriate dosing, standardization and validation of laboratory monitoring, mitigation of thrombotic risk, and development of guidelines for perioperative treatment. Emerging agents aim to broaden targets and improve safety. Building high-quality evidence remains essential to advancing global, patient-centered anticoagulant and hemostatic care.
No takes yet. Share an insight, caveat, or question.
Rocca et al. (2026) conducted a review in Major bleeding events requiring anticoagulation reversal. Antidotes for anticoagulation reversal was evaluated. Pharmacologic reversal of anticoagulants relies on specific antidotes like idarucizumab and andexanet alfa, though challenges remain regarding dosing, monitoring, and thrombotic risk mitigation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: